GLG News by Physicians who Treat Onychomycosis (US)

If Melafinds phase three study results are positive then physicians will in general be receptive. The only issues are: 1. Ease of use/time to scan 2. Ability for non physician personnel to be trained to use the technology. 3. cost 4. Insurance reimbursement The technology may have more use at larger...

The new Modus product "without hydroquinone" cannot be fully evaluated on the basis of the currently available information. Decisions based on the opinions of a "Beauty Editor", and 6 years worth of studies with only 4 patients, are tenuous at best, and laughable at worst. It will be difficult to unseat...

The possible ban of over the counter hydroquinone skin bleaching agents may be premature. We have used these agents for 20 years without any significant side effects including ochronosis or paradoxical darkening of the skin. These agents are only modestly effective at best. Most patients still...

The recent Epiceram phase 4 data comparing it to Cutivate are positive, and bode well for the product. The concept of barrier repair makes sense in light of the recent findings in regards to the genetic basis of atopic dermatitis. Repairing the barrier with Epiceram will reduce inflammation, and the...

Altabax (retapamulin) will be a competitive topical agent for impetigo because it is a new molecular entity, Bactroban or mupirocin is generic and cannot compete directly, and it is indicated for children as young as 9 months. The market for a nonoral antibiotic is always good, due to lower side ef...

WHAT ARE THE PROPER USES OF ANTIBIOTICS ON INFECTED SITES, "CLEAN SITES", POST-OP SITES, ETC.?AN ANALYSIS OF TODAY'S THINKING.FOR IMPETIGO IT WILL BE USED, IT WILL NOT REPLACE EXISTING MODALITIES, BUT WILL SUPPLEMENT, AND HAVE THE ADVANTAGE OF NOT BEING USED SYSTEMICALLY.ROBERT AUERBACH, MD

ELEVESS received its CE mark approval in Europe. The product is entering a crowded field with no real differentiating factors other than having lidocaine as an anesthetic. To release this product in the US without a partnership with an established company will be very hard. It will not be easy to compete...

IT MAY LAST LONGER, PROBABLY MORE EXPENSIVE, INJECTION TECHNIQUE MAY BE MORE CRITICAL IF IT LAST LONGER, I.E. MORE VISCOUS LESS MALLEABLE.  HOW MUCH CLINICAL DATA IS AVAILABLE?HAVING USED FILLER MATERIAL FOR OVER 25 YEARS I HAVE EXPERIENCE WITH ALL OF THEM LONG-TERM.ROBERT AUERBACH, MD

The phase 2 data for Incyclinide indicate a modest benefit over placebo for the 20 mg dose only, which drops off at 12 weeks. This drug will need a higher dose for efficacy. The premise behind a non antimicrobial antibiotic type medication is valid and intriguing. The next trial results are important...

 Jones fractures are traditionally difficult to manage.  Wright Medical has a good range of sizes and lengths of screws. Because of the sizes, style, and lengths of this screws there may be other foot and ankle applications in the future. The percutaneous application will reduce make...